Issa, Ghayas C. http://orcid.org/0000-0002-4339-8683
Ravandi, Farhad
DiNardo, Courtney D. http://orcid.org/0000-0001-9003-0390
Jabbour, Elias http://orcid.org/0000-0003-4465-6119
Kantarjian, Hagop M. http://orcid.org/0000-0002-1908-3307
Andreeff, Michael http://orcid.org/0000-0002-1144-1958
Article History
Received: 28 February 2021
Revised: 19 May 2021
Accepted: 24 May 2021
First Online: 15 June 2021
Conflict of interest
: G.C.I. received research funding from Celgene, Kura Oncology, Syndax and Novartis, and received consultancy fees from Novartis and Kura Oncology. F.R. received research funding from Amgen, Bristol-Myers Squibb, Sunesis Pharmaceuticals, Pfizer, Xenecor, Macrogenetics, Taiho, Astex, Abbvie and honoraria for consulting or advisory role from Jazz, Amgen, Celgene, Astellas, Syros, Taiho, Novartis, AstraZeneca, Agios, Bristol Myers Squibb. C.D.D. received research funding from Abbvie, Agios, Calithera, Cleave, BMS/Celgene, Daiichi-Sankyo, Forma, ImmuneOnc, Loxo, and received consultancy or advisory board fees from AbbVie, Agios, Novartis, Agios, Aprea, Celgene/BMS, ImmuneOnc, Notable Laboratories, and Takeda. E.J. received research funding from Abbvie, Adaptive Biotechnologies, Amgen, Bristol-Myers Squibb, Pfizer and Takeda and received advisory board fees from Genetech. H.M.K. received research funding from Ariad, Astex, Bristol-Myers Squibb, Cyclacel, Daiichi-Sankyo, Pfizer, Immunogen, Jazz, Novartis and honoraria from Pfizer, Immunogen, Actinium and Takeda. M.A. received research funding from Daiichi Sankyo, and consultancy honoraria from Jazz, Celgene, Amgen, AstaZeneca, Dimensions Capital, and equity ownership from Reata, Aptose, Europics, Senti Bio, Chimerix, Oncolyze.